Astria Therapeutics’ (ATXS) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a research note published on Wednesday morning,Benzinga reports. They currently have a $47.00 target price on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Astria Therapeutics’ FY2025 earnings at ($2.38) EPS.

Several other brokerages have also commented on ATXS. JMP Securities assumed coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective for the company. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, March 11th. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective (up from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $30.00.

Astria Therapeutics Price Performance

NASDAQ ATXS opened at $3.96 on Wednesday. The business’s 50-day moving average is $5.01 and its 200 day moving average is $7.40. The stock has a market capitalization of $223.48 million, a PE ratio of -1.89 and a beta of 0.45. Astria Therapeutics has a 1 year low of $3.56 and a 1 year high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). As a group, equities research analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

Several hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its holdings in shares of Astria Therapeutics by 70.5% during the third quarter. Barclays PLC now owns 92,651 shares of the biotechnology company’s stock valued at $1,020,000 after purchasing an additional 38,321 shares during the last quarter. Teacher Retirement System of Texas bought a new position in Astria Therapeutics during the 4th quarter valued at approximately $91,000. KLP Kapitalforvaltning AS bought a new position in Astria Therapeutics during the 4th quarter valued at approximately $41,000. American Century Companies Inc. raised its stake in Astria Therapeutics by 9.9% during the fourth quarter. American Century Companies Inc. now owns 42,693 shares of the biotechnology company’s stock valued at $382,000 after buying an additional 3,839 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Astria Therapeutics by 101.7% in the third quarter. JPMorgan Chase & Co. now owns 39,144 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 19,735 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.